Sangamo Therapeutics Statistics
Total Valuation
SGMO has a market cap or net worth of $103.87 million. The enterprise value is $57.10 million.
| Market Cap | 103.87M |
| Enterprise Value | 57.10M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SGMO has 203.67 million shares outstanding. The number of shares has increased by 13.02% in one year.
| Shares Outstanding | 203.67M |
| Shares Change (YoY) | +13.02% |
| Shares Change (QoQ) | +0.27% |
| Owned by Insiders (%) | 7.71% |
| Owned by Institutions (%) | 56.50% |
| Float | 165.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.60 |
| Forward PS | 3.09 |
| PB Ratio | 1.28 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.32 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.98, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.98 |
| Quick Ratio | 1.75 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -131.00% and return on invested capital (ROIC) is -235.40%.
| Return on Equity (ROE) | -131.00% |
| Return on Assets (ROA) | -89.60% |
| Return on Capital (ROIC) | -235.40% |
| Revenue Per Employee | $435,141 |
| Profits Per Employee | -$636,620 |
| Employee Count | 405 |
| Asset Turnover | 0.61 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -5.07M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -68.43% in the last 52 weeks. The beta is 1.35, so SGMO's price volatility has been higher than the market average.
| Beta (1Y) | 1.35 |
| 52-Week Price Change | -68.43% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.72 |
| Relative Strength Index (RSI) | 39.24 |
| Average Volume (30 Days) | 2,433,251 |
Short Selling Information
The latest short interest is 11.41 million, so 5.60% of the outstanding shares have been sold short.
| Short Interest | 11.41M |
| Short Previous Month | 10.88M |
| Short % of Shares Out | 5.60% |
| Short % of Float | 6.91% |
| Short Ratio (days to cover) | 5.05 |
Income Statement
In the last 12 months, SGMO had revenue of $176.23 million and -$257.83 million in losses. Loss per share was -$1.48.
| Revenue | 176.23M |
| Gross Profit | 176.23M |
| Operating Income | -274.01M |
| Pretax Income | -262.90M |
| Net Income | -257.83M |
| EBITDA | -240.71M |
| EBIT | -262.90M |
| Loss Per Share | -$1.48 |
Balance Sheet
The company has $82.50 million in cash and $33.52 million in debt, giving a net cash position of $48.99 million or $0.24 per share.
| Cash & Cash Equivalents | 82.50M |
| Total Debt | 33.52M |
| Net Cash | 48.99M |
| Net Cash Per Share | $0.24 |
| Equity / Book Value | 82.89M |
| Book Value Per Share | 0.41 |
| Working Capital | 46.60M |
Cash Flow
In the last 12 months, operating cash flow was -$224.84 million and capital expenditures -$21.16 million, giving a free cash flow of -$246.00 million.
| Operating Cash Flow | -224.84M |
| Capital Expenditures | -21.16M |
| Free Cash Flow | -246.00M |
| FCF Per Share | -$1.41 |
Margins
Gross margin is 100.00%, with operating and profit margins of -155.48% and -146.30%.
| Gross Margin | 100.00% |
| Operating Margin | -155.48% |
| Pretax Margin | -149.18% |
| Profit Margin | -146.30% |
| EBITDA Margin | -136.59% |
| EBIT Margin | -149.18% |
| FCF Margin | -139.59% |
Dividends & Yields
SGMO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.02% |
| Shareholder Yield | -13.02% |
| Earnings Yield | -243.03% |
| FCF Yield | -231.87% |
Analyst Forecast
The average price target for SGMO is $4.64, which is 807.85% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.64 |
| Price Target Difference | 807.85% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 12.36% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SGMO has an Altman Z-Score of -14.98 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.98 |
| Piotroski F-Score | 3 |